Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.scib.2025.06.028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PTEN-mediated senescence of lung epithelial cells drives ventilator-induced pulmonary fibrosis.
Theranostics
August 2025
Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Mechanical ventilation (MV), a life-saving intervention for acute respiratory distress syndrome (ARDS), may exacerbate pulmonary fibrosis (PF) through unclear mechanisms. Although Phosphatase and Tensin homolog (PTEN) suppresses chronic PF, its role in MV-induced PF remains unknown. This study will determine whether PTEN mediates MV-PF via lung epithelial cell senescence.
View Article and Find Full Text PDFIdasanutlin-ionizable lipid nanocomplex for enhanced solubility, stability, and anticancer activity in p53 sensitive lung cancer.
Colloids Surf B Biointerfaces
December 2025
College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11432, USA. Electronic address:
Lung cancer is a leading cause of cancer-related mortality worldwide due to increasing incidence and poor clinical outcomes. Over 50 % of human cancers involve alterations in the tumor suppressor protein p53, mostly resulting in loss of function. Idasanutlin (IDA), a hydrophobic, anionic molecule, is a potent MDM2 inhibitor capable of restoring p53 activity in cancers retaining wild-type (WT) p53.
View Article and Find Full Text PDFRG7388 inhibits SFTSV replication by suppressing MDM2-mediated p53 degradation and preventing apoptosome disruption.
Sci Bull (Beijing)
June 2025
School of Life Sciences, Tianjin University, Tianjin 300072, China; State Key Laboratory of Synthetic Biology, Tianjin University, Tianjin 300072, China. Electronic address:
Repurposing MDM2 inhibitor RG7388 for TP53-mutant NSCLC: a p53-independent pyroptotic mechanism via ROS/p-p38/NOXA/caspase-3/GSDME axis.
Cell Death Dis
June 2025
Department of Oncology, Weifang People's Hospital, the First Affiliated Hospital of Shandong Second Medical University, Weifang, China.
Non-small cell lung cancer (NSCLC) is highly malignant with limited treatment options, largely due to the inherent tumoral heterogeneity and acquired resistance towards chemotherapy and immunotherapy. RG7388, a known MDM2 inhibitor, exhibited anticancer activity in TP53-wild-type (TP53) NSCLC by triggering the p53/PUMA axis-dependent apoptosis. However, our study uncovered previously unrecognized p53-independent anticancer effects of RG7388 in TP53-mutant (TP53) NSCLC, although the underlying mechanisms remained elusive.
View Article and Find Full Text PDFEzetimibe Anticancer Activity via the p53/Mdm2 Pathway.
Biomedicines
January 2025
Department of Life & Consumer Sciences, College of Agriculture and Environmental Sciences, University of South Africa, Cnr. Pioneer and Christiaan de Wet Roads, B2-010 Calabash Building, Florida, Johannesburg 1710, South Africa.
Background: Ezetimibe is used to treat cardiovascular disease as it blocks the sterol transporter Niemann-Pick C1-Like 1 (NPC1CL1) protein. However, recent evidence indicates that Ezetimibe inhibits several cancers indirectly by reducing circulating cholesterol or via specific signalling pathways.
Methods And Results: Our in silico studies indicate that Ezetimibe binds to the Tp53 binding domain in Mdm2, forming a more thermodynamically stable complex than nutlin3a.